{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-015154","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2023-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.159109+00:00","generated_at":"2026-06-20T09:33:28.196622+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Magenta pauses MGTA-117 Phase 1/2 trial after participant death possibly related to drug","bullets":["Latest participant dosed at Cohort 3 level (0.08 mg/kg) experienced Grade 5 SAE: respiratory failure and cardiac arrest leading to death.","Death deemed possibly related to MGTA-117; reported to FDA as Suspected Unexpected Serious Adverse Reaction (SUSAR).","Magenta voluntarily paused dosing after consultation with the trial's safety Cohort Review Committee.","Trial is in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-015154","json":"https://secwatch.observer/filing/0001193125-23-015154.json","markdown":"https://secwatch.observer/filing/0001193125-23-015154.md","text":"https://secwatch.observer/filing/0001193125-23-015154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523015154/0001193125-23-015154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523015154/d395574d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T09:33:28.196622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}